Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports

In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Vanessa D., Pellegrini, Patricia, Rotman, Vivian, Pittella, Ana Maria, Nunes, Estevão P., Lago, Barbara V., Lampe, Elisabeth, Mello, Francisco C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893792/
https://www.ncbi.nlm.nih.gov/pubmed/31683616
http://dx.doi.org/10.3390/v11111004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893792/
https://www.ncbi.nlm.nih.gov/pubmed/31683616
http://dx.doi.org/10.3390/v11111004

Ejemplares similares